Evidence map›Paper›PMID 42620782›Full record

ArticleClinical case reports2026

Clinical and Biochemical Improvement After Switching From Agalsidase Alfa to Beta in a Boy With Classic Fabry Disease: A Case Report.

Nobuhiko Koga, Hiroaki Yodogawa, Takaaki Sawada, Yuichi Mushimoto, Shinichiro Nagamitsu, Kimitoshi Nakamura, Shinichi Hirose, Takahito Inoue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nobuhiko KogaDepartment of Pediatrics, School of Medicine Fukuoka University Fukuoka Japan.ORCID https://orcid.org/0009-0008-7033-3819
Hiroaki YodogawaDepartment of Pediatrics, School of Medicine Fukuoka University Fukuoka Japan.
Takaaki SawadaDepartment of Pediatrics Kumamoto University Hospital Kumamoto Japan.ORCID https://orcid.org/0000-0002-9256-7551
Yuichi MushimotoDepartment of Pediatrics, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.ORCID https://orcid.org/0000-0003-2442-541X
Shinichiro NagamitsuDepartment of Pediatrics, School of Medicine Fukuoka University Fukuoka Japan.
Kimitoshi NakamuraDepartment of Pediatrics Kumamoto University Hospital Kumamoto Japan.
Shinichi HiroseGeneral Medical Research Center, School of Medicine Fukuoka University Fukuoka Japan.
Takahito InoueDepartment of Pediatrics, School of Medicine Fukuoka University Fukuoka Japan.ORCID https://orcid.org/0000-0003-2496-5424

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We described a 12-year-old boy with classic Fabry disease who was diagnosed through newborn screening. At age 6.2, he started agalsidase alfa based on evidence of subclinical organ involvement. At age 7.2, acroparesthesia subsequently developed. At age 10.9, after switching to agalsidase beta due to an insufficient clinical and biochemical response, his acroparesthesia resolved and plasma Lyso-Gb3 decreased. This report broadens the clinical understanding of children with Fabry disease.

Indexed as

biomarkerdrug antibodyenzymefabry diseaselysosome

Identifiers

PMID42620782
PMCPMC13486963

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.